دورية أكاديمية
Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD.
| العنوان: | Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD. |
|---|---|
| المؤلفون: | Vilorio-Marqués, Laura, Castañón Fernández, Christelle, Mora, Elvira, Gutiérrez, Lorena, Rey Bua, Beatriz, Jiménez Lorenzo, Maria José, Díaz Beya, Marina, Vara Pampliega, Miriam, Molero, Antonieta, Sánchez-García, Joaquín, Calabuig, Marisa, Cedena, Maria Teresa, Chen-Liang, Tzu, Díaz Santa, Johana Alejandra, Padilla, Irene, Hernández, Francisca, Díez, Rosana, Asensi, Pedro, Xicoy, Blanca, Sanz, Guillermo, Valcárcel, David, Diez-Campelo, María, Bernal, Teresa |
| سنة النشر: | 2022 |
| المجموعة: | Sistema Sanitario Público de Andalucía (SSPA): Repositorio |
| مصطلحات موضوعية: | acute myeloid leukemia, hypomethylating agent, infection, myelodysplastic syndrome, treatment outcome |
| الوصف: | The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. We aimed to evaluate whether infectious events (IEs) negatively influenced the results of HMA treatment in a real-world setting. Observational study. We obtained data from 412 non-selected consecutive patients from 23 Spanish hospitals who were diagnosed with high-risk myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia and were treated with HMA. HMAs received after chemotherapy or stem cell transplant were excluded. All IEs were recorded. Outcomes included OS, modifications to the pre-planned treatment, incidence and characteristics of IEs, hospitalization, red blood cell transfusions, and factors associated with infection. The rate of infection was 1.2 per patient/year. Next-cycle delay (p = 0.001) and hospitalizations (p = 0.001) were significantly influenced by IEs. Transfusion requirements during each cycle were significantly higher after infection compared with cycles without infection (coefficient = 1.55 [95% confidence interval (CI) = 1.26-1.84], p 20% (HR = 1.57 [95% CI = 1.19-2.01], p 9 g/dl (HR = 0.65 [95% CI = 0.51-0.82], p HMA infectious toxicity worsens OS, hinders the adherence to antineoplastic treatment and results in significant morbidity. Preventive strategies are fundamental in vulnerable patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2040-6207 |
| العلاقة: | http://hdl.handle.net/10668/20232Test; PMC9527993; https://doi.org/10.1177/20406207221127547Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527993/pdfTest |
| DOI: | 10.1177/20406207221127547 |
| الإتاحة: | https://doi.org/10.1177/20406207221127547Test http://hdl.handle.net/10668/20232Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527993/pdfTest |
| حقوق: | Attribution-NonCommercial 4.0 International ; http://creativecommons.org/licenses/by-nc/4.0Test/ ; open access |
| رقم الانضمام: | edsbas.4D684263 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 20406207 |
|---|---|
| DOI: | 10.1177/20406207221127547 |